Early melanoma diagnosis is the best and most cost effective method to prevent metastatic melanoma but the diagnosis of malignancy is not absolute. Metastatic patients have a poor prognosis and are expensive to treat. Metastatic patients are treated with inhibitors but many do not respond or experience a relapse of disease. Currently there is a lack of a clinically useful blood and tissue-based test of disease activity. This study will develop a biomarker diagnostic kit for use with melanoma patients with the goal of guiding treatment, better predicting patient outcomes and reducing health care costs.